News Excerpt:
Serum Institute's Cervavac, a quadrivalent HPV vaccine, found safe and comparable to Gardasil in a phase-2/3 trial in India.

About the news:

• The trial found that two doses of the Serum’s Cervavac vaccine generated nearly double the antibody response against HPV subtypes compared with the response generated with Gardasil vaccine.
• The study focused on adolescents, as the effectiveness of the HPV vaccine tends to be higher when administered at a younger age.
• Serum's vaccine was evaluated based on WHO's recommendations, using an immunobridging approach, comparing immune responses with the efficacy-proven population of women aged 15-26 who received Gardasil.